WebAug 7, 2014 · This finding suggests that Chk1 inhibitors either as single agents or in combination chemotherapy represents a viable therapeutic option for the treatment of triple-negative breast cancer. pChk1 (S296) tumor expression levels could serve as a useful biomarker to stratify patients who might benefit from Chk1 inhibitor therapy. Peer Review … WebCitations: (65) Cell Signaling Technology's Phospho-Chk1 (Ser296) Antibody is a Rabbit Polyclonal antibody. This antibody has been shown to work in applications such as: Western Blot. Phospho-Chk1 (Ser296) Antibody detects endogenous levels of Chk1 only when phosphorylated at serine 296.
Resistance to the CHK1 inhibitor prexasertib involves ... - Nature
WebAug 7, 2014 · Inhibition of Chk1 in these sensitive cell lines induced DNA damage and caspase-3/7 dependent apoptosis. Western blot profiling identified pChk1 (S296) as a predictive biomarker of Chk1 inhibitor sensitivity in ovarian and triple-negative breast cancer and pH2AX (S139) in luminal breast cancer. WebJul 4, 2014 · In all combination treatment regimens, total Chk1 as well as phospho-Chk1 S296, S317 and S345 were decreased and γH2AX increased compared to camptothecin … jeostili
Human Phospho-CHK1 (Ser296) and Total CHK1 ELISA Kit
WebChemotherapy- or radiotherapy-induced DNA damage activates the Chk1-dependent DNA damage response (DDR) and cell cycle checkpoints to facilitate cell survival. Numerous … WebJul 9, 2024 · CHK1 is phosphorylated by ATR at S317 and S345 , and to a lesser extent by ATM on S317 , a prerequisite for autophosphorylation at S296 for full activation of CHK1 (Fig. 1e) . WebSep 2, 2015 · Basal CHK1 (S296) autophosphorylation was reduced 3- to 3.5-fold between 4 hours and 12 hours following dosing with activity restored by 24 hours. CHK1 inhibition tracked with drug exposure in the blood, with measured plasma exposures of 7 ng/mL at 12 hours and 3 ng/mL by 24 hours . This was ... lama ai faseeh